MetaCap

Compugen Ltd. Company Profile

NASDAQ: CGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.84-0.04 (-2.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Compugen at a glance

Compugen Ltd. (NASDAQ: CGEN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Holon, Israel. Compugen is led by Dr. Eran Ophir Ph.D. and employs about 75 people. The company's shares have traded publicly since 2000.

At a market capitalization of $177.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001119774, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Compugen do?

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Business description based on the company's public filings.

Company information

Legal name
Compugen Ltd.
Ticker
NASDAQ: CGEN
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Eran Ophir Ph.D.
Employees
75
Headquarters
Azrieli Center, Holon, Israel
Phone
972 3 765 8585
Website
cgen.com
IPO year
2000
Market cap
$177.82M
SEC CIK
0001119774

Companies similar to Compugen

CGEN peer companies
CompanyPrice% ChgMarket capCompare
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs CGEN
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs CGEN
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs CGEN
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs CGEN
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs CGEN
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs CGEN
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs CGEN
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs CGEN

Related